共被期刊论文引用了4次
您的检索式：您选中1篇文献正在查看引证文献汇总
|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | New frontiers in proton therapy:applications in cancers显示文摘Proton therapy offers dominant advantages over photon therapy due to the unique depth-dose characteristics of proton,which can cause a dramatic reduction in normal tissue doses both distal and proximal to the tumor target volume.In turn,this feature may allow dose escalation to the tumor target volume while sparing the tumor-neighboring susceptible organs at risk,which has the potential to reduce treatment toxicity and improve local control rate,quality of life and survival.Some dosimetric studies in various cancers have demonstrated the advantages over photon therapy in dose distributions.Further,it has been observed that proton therapy confers to substantial clinical advantage over photon therapy in head and neck,breast,hepatocellular,and non-small cell lung cancers.As such,proton therapy is regarded as the standard modality of radiotherapy in many pediatric cancers from the technical point of view.However,due to the limited clinical evidence,there have been concerns about the high cost of proton therapy from an economic point of view.Considering the treatment expenses for late radiation-induced toxicities,cost-effective analysis in many studies have shown that proton therapy is the most cost-effective option for brain,head and neck and selected breast cancers.Additional studies are warranted to better unveil the cost-effective values of proton therapy and to develop newer ways for better protection of normal tissues.This review aims at reviewing the recent studies on proton therapy to explore its benefits and cost-effectiveness in cancers.We strongly believe that proton therapy will be a common radiotherapy modality for most types of solid cancers in the future. | Tai-Ze Yuan Ze-Jiang Zhan Chao-Nan Qian | 2019 | Cancer Communications2019，39，1： | 3 |
| 2 | 硼中子俘获治疗的临床研究进展显示文摘硼中子俘获治疗(BNCT)是一种先进的肿瘤精准放疗方法。在BNCT中先利用硼携带剂使10B在肿瘤细胞内靶向富集,然后利用热中子束照射肿瘤,基于热中子和10B的核裂变反应释放的α粒子和7Li粒子杀伤肿瘤细胞。与常规放疗相比,BNCT具有生物学效应高、靶向精准、正常组织损伤小和治疗次数少等特点。本文将对近年BNCT的临床研究进展和存在的问题进行综述。 | 张环宇 张鹏程 祝猷哲 冉俊涛 | 2023 | 中华放射肿瘤学杂志2023，32，9： | 0 |
| 3 | 硼中子俘获疗法治疗头颈部恶性肿瘤的临床研究进展显示文摘硼中子俘获疗法(BNCT)是一种基于10B(n,α)7Li反应治疗肿瘤的方法,硼(10B)化合物携带剂进入人体后选择性富集于肿瘤细胞内,与外照射中子发生反应,由于产生的7Li(4 μm)和α粒子(7 μm)会沉积在一个细胞量级(10 μm),因此可以达到定向局域性杀死肿瘤细胞且对正常组织伤害较小的目的。迄今为止,BNCT已经在多种肿瘤进行了临床研究,包括多形性胶质母细胞瘤、脑膜瘤、头颈部肿瘤、肺癌等。本文主要介绍BNCT治疗头颈部肿瘤的临床研究进展。 | 伍艳萍 罗凤霞 李月敏 | 2024 | 中华放射肿瘤学杂志2024，33，1： | 0 |
| 4 | 硼中子俘获治疗靶向硼携带剂4-硼-L-苯丙氨酸患者体内生物分布显示文摘硼中子俘获治疗(boron neutron capture therapy, BNCT)是二元靶向放射治疗方法,中子并不直接提供肿瘤治疗剂量,而是利用肿瘤靶向10B携带剂将10B(n, α)7Li俘获反应产生的剂量沉积于肿瘤细胞。因此了解血液、肿瘤组织和正常组织中10B携带剂的生物分布对于BNCT临床治疗是必不可少的。目前国际上BNCT临床主要使用4-硼-L-苯丙氨酸(4-borono-L-phenylalanine, BPA)为硼携带剂。本文简要总结了BPA的结构、理化特性、细胞摄取机制以及人体生物分布等数据,目的是支持和促进基于BPA的BNCT临床试验准备。 | 祝夏阳 刘凯 邵玉军 金从军 赵春元 崇奕峥 郭志滨 孙琪 刘志博 刘彤 张紫竹 | 2023 | 核化学与放射化学2023，45，6： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员